BR112019002729A2 - composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida - Google Patents
composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólidaInfo
- Publication number
- BR112019002729A2 BR112019002729A2 BR112019002729-7A BR112019002729A BR112019002729A2 BR 112019002729 A2 BR112019002729 A2 BR 112019002729A2 BR 112019002729 A BR112019002729 A BR 112019002729A BR 112019002729 A2 BR112019002729 A2 BR 112019002729A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- solid pharmaceutical
- preparing
- solid
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16184053.3 | 2016-08-12 | ||
EP16184053 | 2016-08-12 | ||
PCT/EP2017/070215 WO2018029262A1 (en) | 2016-08-12 | 2017-08-09 | Solid pharmaceutical composition comprising amorphous sofosbuvir |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019002729A2 true BR112019002729A2 (pt) | 2019-05-14 |
Family
ID=56684527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019002729-7A BR112019002729A2 (pt) | 2016-08-12 | 2017-08-09 | composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida |
Country Status (11)
Country | Link |
---|---|
US (1) | US20190167706A1 (pt) |
EP (1) | EP3496705A1 (pt) |
JP (1) | JP2019530645A (pt) |
KR (1) | KR20190038881A (pt) |
CN (1) | CN109862884A (pt) |
AU (1) | AU2017309302A1 (pt) |
BR (1) | BR112019002729A2 (pt) |
CA (1) | CA3033319A1 (pt) |
MX (1) | MX2019001771A (pt) |
RU (1) | RU2019106294A (pt) |
WO (1) | WO2018029262A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110214711B (zh) * | 2019-06-28 | 2024-07-26 | 昱庆塑胶五金制品(惠州)有限公司 | 智能宠物喂食器 |
CN111467363A (zh) * | 2020-04-07 | 2020-07-31 | 中国科学院深圳先进技术研究院 | 索非布韦在制备预防和治疗冠状病毒的药物中的应用 |
CN111773192B (zh) * | 2020-08-18 | 2024-08-02 | 福建广生堂药业股份有限公司 | 一种索磷布韦片剂及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
UY33311A (es) | 2010-03-31 | 2011-10-31 | Pharmasset Inc | Fosforamidatos de nucleosidos |
EP2907505A3 (en) | 2011-12-29 | 2015-12-30 | Abbvie Inc. | Solid compositions comprising an HCV inhibitor |
US20170080008A1 (en) * | 2014-03-05 | 2017-03-23 | Galenicum Health S.L. | Stable pharmaceutical compositions of sofosbuvir |
AU2015239018A1 (en) * | 2014-04-03 | 2016-10-13 | Sandoz Ag | Solid composition comprising amorphous sofosbuvir |
WO2016038542A2 (en) * | 2014-09-10 | 2016-03-17 | Mylan Laboratories Limited | Polymorphic forms of sofosbuvir |
CN104586802B (zh) * | 2015-02-02 | 2018-01-16 | 长春海悦药业股份有限公司 | 一种含有索菲布韦的药物组合物 |
-
2017
- 2017-08-09 KR KR1020197006578A patent/KR20190038881A/ko unknown
- 2017-08-09 JP JP2019507117A patent/JP2019530645A/ja active Pending
- 2017-08-09 RU RU2019106294A patent/RU2019106294A/ru not_active Application Discontinuation
- 2017-08-09 CN CN201780063084.5A patent/CN109862884A/zh not_active Withdrawn
- 2017-08-09 AU AU2017309302A patent/AU2017309302A1/en not_active Abandoned
- 2017-08-09 WO PCT/EP2017/070215 patent/WO2018029262A1/en unknown
- 2017-08-09 US US16/324,674 patent/US20190167706A1/en not_active Abandoned
- 2017-08-09 BR BR112019002729-7A patent/BR112019002729A2/pt not_active Application Discontinuation
- 2017-08-09 CA CA3033319A patent/CA3033319A1/en not_active Abandoned
- 2017-08-09 EP EP17749723.7A patent/EP3496705A1/en not_active Withdrawn
- 2017-08-09 MX MX2019001771A patent/MX2019001771A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN109862884A (zh) | 2019-06-07 |
RU2019106294A (ru) | 2020-09-21 |
JP2019530645A (ja) | 2019-10-24 |
WO2018029262A1 (en) | 2018-02-15 |
AU2017309302A1 (en) | 2019-02-21 |
CA3033319A1 (en) | 2018-02-15 |
MX2019001771A (es) | 2019-11-18 |
US20190167706A1 (en) | 2019-06-06 |
EP3496705A1 (en) | 2019-06-19 |
KR20190038881A (ko) | 2019-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP18008905A (es) | Tricíclicos sustituidos y método para usarlos. | |
GEP20217239B (en) | Pharmaceutical composition | |
CR20180564A (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que lo contienen | |
BR112018000729A2 (pt) | métodos e composições para o aprimoramento de traços de plantas | |
DK3529248T3 (da) | Farmaceutiske sammensætninger | |
BR112016017175A2 (pt) | Embalagem para acondicionamento de um artigo, e método para formar uma embalagem | |
BR112016021682A2 (pt) | cenicriviroc para o tratamento da fibrose | |
BR112018006696A2 (pt) | métodos e sistemas para obter óleo a partir de uma composição de vinhoto | |
BR112018004056A2 (pt) | material hemostático, método para produzir um material hemostático, e, kit | |
GEP20217240B (en) | Pharmaceutical composition | |
BR112017025427A2 (pt) | composição farmacêutica oral | |
BR112018070497A2 (pt) | métodos e formulações farmacêuticas para tratamento de condições oculares | |
FI20155621A (fi) | Menetelmä ja tuote | |
DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
MA47516A (fr) | Composition pharmaceutique | |
DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf | |
BR112016028083A2 (pt) | Composição oral farmacêutica de isotretinoina e seu processo de preparação | |
BR112019002729A2 (pt) | composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida | |
BR112017008097A2 (pt) | método para tratar condições oculares | |
BR112017017883A2 (pt) | doses e métodos para administrar telavancina | |
KR102374939B9 (ko) | 경화성 조성물, 경화물 및 경화물의 제조 방법 | |
IT201700016964A1 (it) | Composizione per la tosse | |
BR112016026684A2 (pt) | Fertilizante à base de enxofre | |
FI20155729A (fi) | Menetelmä ja tuote | |
DK3089740T3 (da) | Farmaceutisk sammensætning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |